The sales forecast for the fiscal year ending March 2026 has been revised upward to \u00a539.5 billion (4.5% increase from previous forecast), while operating income was revised downward to \u00a5400 million (84.6% decrease), and net income attributable to owners of parent was revised downward to \u00a51.6 billion (46.7% decrease).<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4552","jir_company_name":"JCR Pharmaceuticals Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-01-28","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/01\/4552-20260128-02.pdf","jir_short_summary":"The sales forecast for the fiscal year ending March 2026 has been revised upward to \u00a539.5 billion (4.5% increase from previous forecast), while operating income was revised downward to \u00a5400 million (84.6% decrease), and net income attributable to owners of parent was revised downward to \u00a51.6 billion (46.7% decrease).","jir_summary":"### Overview of Earnings Forecast Revision\nJCR Pharmaceuticals Co., Ltd. has revised its full-year consolidated earnings forecast for the fiscal year ending March 2026. Net sales were revised upward to \u00a539.5 billion (an increase of \u00a51.7 billion or 4.5%) due to strong performance of treatments for renal anemia and Fabry disease. Conversely, operating income was significantly revised downward to \u00a5400 million (a decrease of \u00a52.2 billion or 84.6%) due to the recording of upfront payments from licensing agreements and increased depreciation expenses. Ordinary income was similarly revised downward to \u00a5400 million (83.3% decrease), and net income attributable to owners of parent was revised to \u00a51.6 billion (a decrease of \u00a51.4 billion or 46.7%).\n\n### Reasons for Revision and Future Outlook\nThe increase in net sales is driven by healthy sales of renal anemia and Fabry disease treatments. On the expense side, research and development expenses include an upfront payment of \u00a51.5 billion for the exclusive license agreement of givinostat, a treatment for Duchenne muscular dystrophy acquired from Italfarmaco. Additionally, selling, general and administrative expenses increased due to higher depreciation costs for the Kobe Science Park Center. The dividend forecast remains unchanged. The company will continue to monitor market trends closely and strive to improve earnings.","jir_financial_highlights":"Net Sales: 39,500 million yen (4.5% increase from previous forecast)\nOperating Income: 400 million yen (84.6% decrease from previous forecast)\nOrdinary Income: 400 million yen (83.3% decrease from previous forecast)\nNet Income Attributable to Owners of Parent: 1,600 million yen (46.7% decrease from previous forecast)\nNet Income per Share: 13.12 yen (Unknown)","jir_category":"","jir_hashtags":"#JCRPharmaceuticals, #EarningsForecastRevision, #JapaneseStocks","jir_key_figures":"Net Sales: \u00a539,500 million (4.5% increase from previous forecast)\nOperating Income: \u00a5400 million (84.6% decrease from previous forecast)\nNet Income Attributable to Owners of Parent: \u00a51,600 million (46.7% decrease from previous forecast)","jir_meta_title":"JCR Pharmaceuticals Revises Fiscal Year March 2026 Earnings Forecast - Sales Up 4.5% but Profit Significantly Down","jir_meta_description":"JCR Pharmaceuticals has revised its full-year consolidated earnings forecast for the fiscal year ending March 2026, raising net sales to \u00a539.5 billion. However, operating income is sharply reduced to \u00a5400 million, highlighting profitability challenges.","jir_og_title":"JCR Pharmaceuticals Revises Fiscal Year Ending March 2026 Earnings Forecast","jir_og_description":"Net sales are expected to increase, but operating income and net income are forecasted to decline significantly.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Net Sales Trend (million yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"FY March 2025 Actual\\\",\\\"FY March 2026 Previous Forecast\\\",\\\"FY March 2026 Revised Forecast\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Sales\\\",\\\"data\\\":[33072,37800,39500],\\\"backgroundColor\\\":\\\"#4e79a7\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Operating Income Trend (million yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"FY March 2025 Actual\\\",\\\"FY March 2026 Previous Forecast\\\",\\\"FY March 2026 Revised Forecast\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Income\\\",\\\"data\\\":[-6650,2600,400],\\\"backgroundColor\\\":\\\"#f28e2b\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":false}}}}\"}, {\"jir_chart_id\": \"net_profit_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Net Income Attributable to Owners of Parent Trend (million yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"FY March 2025 Actual\\\",\\\"FY March 2026 Previous Forecast\\\",\\\"FY March 2026 Revised Forecast\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Income\\\",\\\"data\\\":[-4759,3000,1600],\\\"backgroundColor\\\":\\\"#e15759\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":false}}}}\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Net Sales Breakdown Forecast for FY March 2026 (million yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Growject\u00ae\\\",\\\"Iscargo\u00ae\\\",\\\"Temcell\u00ae HS Injection\\\",\\\"Renal Anemia Therapeutics\\\",\\\"Epoetin Alfa BS Injection \\\\\\\"JCR\\\\\\\"\\\",\\\"Darbepoetin Alfa BS Injection \\\\\\\"JCR\\\\\\\"\\\",\\\"Agalsidase Beta BS Intravenous Injection \\\\\\\"JCR\\\\\\\"\\\",\\\"Pharmaceuticals Total\\\",\\\"Contract Revenue\\\",\\\"Others\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Previous Forecast\\\",\\\"data\\\":[17800,6400,2700,3100,800,2300,1100,31100,5500,1200],\\\"backgroundColor\\\":\\\"#76b7b2\\\"},{\\\"label\\\":\\\"Revised Forecast\\\",\\\"data\\\":[17800,6400,2700,3600,1100,2500,1600,32100,5800,1600],\\\"backgroundColor\\\":\\\"#59a14f\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}]","ir_related_company":9680,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"earnings_guidance","footnotes":""},"sector":[],"importance":[],"class_list":["post-21426","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n